Southern Glazer's Wine & Spirits Youth Alcohol Awareness Program Continues Efforts to Prevent Underage Drinking
The Youth Alcohol Awareness and Education Foundation, Inc. – founded by Southern Glazer's, to support the prevention of underage drinking – today announced that the Alcohol Education for High School online courses will return for the 2025-2026 school year.
AlcoholEdu for High School, developed by EverFi, a company that delivers digital education on critical life skills, is a 90-minute interactive course designed for high school students. It includes science-based alcohol education, with engaging exercises that challenge perceptions, and encourage positive behaviors. The courses are based on five pillars: Knowing the Basics, Knowing Your Influences, Brain and Body, Smart Decisions, and Future Ready. Its goal is to equip students with the knowledge and awareness to make responsible choices about alcohol.
The most recent 2024-2025 school year was a complete success as students' assessment scores in the AlcoholEdu for High School program in Florida, Texas and New York rose from 62% pre-lesson to 89% post-lesson, resulting in a 27 percent knowledge increase. Overall, 92% of students who took the course say that these educational sessions will help them make informed and thoughtful decisions for the future.
Educators – who play an imperative role in this initiative – reported an extraordinary 94% positive rating across the board: they found value in the material taught in the classroom, noted that students found the materials compelling, and agreed that teacher-provided content was good or better.
'The content was self-contained; it was short enough for the students to stay interested but contained enough information to be educational,' said one of the educators. 'This course helps me get students information that I might not get time to cover in class.'
The program launched in 2017 in South Florida. Southern Glazer's expanded support of the program to Texas in 2019 then New York in 2020. Since its start, the program has made a difference for 54,222 students, 331 high schools and has offered 79,660 hours of learning.
School personnel and administration can reach out to the following individuals for more information on AlcoholEdu:
About Southern Glazer's Wine & Spirits
Southern Glazer's Wine & Spirits is the world's preeminent distributor of beverage alcohol, building brands for moments that matter. The multi-generational, family-owned Company has operations in 47 U.S. markets and Canada, as well as brokerage operations through its Southern Glazer's Travel Retail Sales & Export Division in the Caribbean, Central and South America. In 2025, Southern Glazer's was recognized by Newsweek as one of America's Greatest Workplaces for Diversity and America's Greatest Workplaces for Women, and was ranked by U.S. News & World Report as a Best Company to Work for Overall. Southern Glazer's urges all retail customers and adult consumers to market, sell, serve, and enjoy its products responsibly. For more information visit www.southernglazers.com. Follow us on Facebook, X and Instagram @sgwinespirits.
About EVERFI
EVERFI is an international technology company driving social impact through education to address key societal challenges like financial wellness, mental health, workplace conduct, and more. Founded in 2008, EVERFI has reached millions of K-12 and adult learners worldwide with its transformative digital educational content. Through a unique third-party payer model, EVERFI provides K-12 schools in the U.S. with access to essential educational resources at no cost, ensuring that students everywhere gain vital life skills. Recognized as one of the World's Most Innovative Companies by Fast Company and featured on Fortune Magazine's Impact 20 List and the GSC EdTech 150, EVERFI continues to shape the future of digital learning. To learn more about EVERFI, please visit everfi.com or follow us on Facebook, Instagram, LinkedIn, or X/Twitter @EVERFI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Yahoo
an hour ago
- Yahoo
KonaTel Reports Second Quarter 2025 Results
Diversified Hosted Services Expansion DALLAS, TX / / August 19, 2025 / KonaTel, Inc. (OTCQB:KTEL) ( a voice/data communications holding company, today announced financial results for the three-month period ended June 30, 2025. Second Quarter 2025 Financial Summary Revenues of $2.2 million, down 50.3% compared to the second quarter last year. The decrease in revenue, as discussed with our year-end 2024 results, relates to fewer activations within the Company's Mobile Services ("Lifeline") segment as a result of reduced government subsidized revenues from the cancellation of the Affordable Connectivity Program (the "ACP Program"). Gross profit of $550,240, down 38.8% compared to the second quarter last year. Operating loss of $(1,198,558) compared to operating loss of $(1,254,362) in the second quarter last year. GAAP net loss of $(1,187,641), or $(0.03) per share, compared to GAAP net loss of $(1,109,697), or $(0.03) per share, in the second quarter last year. Non-GAAP net loss of $(942,182), or $(0.02) per diluted share, compared to a Non-GAAP net loss of $(884,571), or $(0.02) per diluted share, in the second quarter of last year. Generally, Q2 revenue, gross profit and non-GAAP income were on par with Q1. Cash remained healthy at $1.5 million, and we have already taken significant steps to further reduce cash burn as our new growth initiatives gain traction. Sean McEwen, Chairman and CEO of KonaTel stated, "As previously stated in our 2024 10K filing, congress' failure to re-fund the ACP Program has negatively impacted our business. We continue to aggressively pursue third-party relationships to expand our Lifeline operation, and we are currently awaiting regulatory approval in the state of California to potentially launch a new partnership before the end of 2025. As part of our ongoing revenue diversification/derisking efforts, we continue to invest in the expansion of our CPaaS ("Communications Platform as a Service") cloud platform, including wholesale SMS and POTS ("Plain Old Telephone Service") wholesale cellular replacement service, specifically designed for telecommunications carriers and resellers." McEwen closed, "The unpredictable behavior of Congress during 2024 negatively impacted our business, but we shifted our development and sales efforts into new areas of expansion. We continue to believe one of our strong advantages comes from our established wholesale cloud CPaaS platform, that supports a variety of services, including termination/origination, VoIP/SIP, SMS, POTS, Mobile Data, and Mobile Voice solutions. Management's focus on our CPaaS business is providing a foundation to derisk the Company through the addition of future, low attrition recurring revenue services, and if we are successful with new distribution partnerships within our government subsidized Lifeline cellular service, we expect to see additional revenues." Quarterly Financial Summary (Q2 2025 vs. Q2 2024) Revenue of $2.2 million, a decrease of 50.3% compared to $4.3 million for the reasons discussed above. The decrease in revenue was primarily due to the loss of mobile services revenues under the ACP Program, which ended on June 1, 2024. Gross profit was $550,240, or 25.5% gross profit margin, compared to $899,707, or 20.7% gross profit margin. This increase primarily resulted from adding higher Average Revenue Per User ("ARPU") activations within our Mobile Services segment, and sourcing lower compensation and network costs. Total operating expenses were $1.7 million, compared to $2.2 million. This decrease was primarily due to lower payroll and related expenses associated with the reduction of headcount in our IM Telecom subsidiary in the fourth quarter of 2024 as well as lower application development costs in our Hosted Services segment. GAAP net loss was $(1,187,641) million, or $(0.03) per diluted share (based on 43.5 million weighted average shares), compared to a net loss of $(1,109,697), or $(0.03) per diluted share (based on 43.4 million weighted average shares). Non-GAAP net loss was $(942,182), or $(0.02) per diluted share, compared to a Non-GAAP net loss of $(884,571), or $(0.02) per diluted share. Balance Sheet The Company ended the quarter with $1.5 million in cash, compared to $3.7 million on June 30, 2024. This decrease was due to a corresponding reduction in operating revenues during the same period. Year-to-Date Financial Detail (First Six Months of 2025 vs. First Six Months of 2024) Revenues decreased 56.6% to $4.3 million compared to $10 million, reflecting a 1% decrease in Hosted Services revenues and an 81% decrease in Mobile Services revenues. Gross profit was $1,202,133 or 27.8% gross profit margin, compared to gross profit of $2 million, or 20.3% gross profit margin. This increase in gross profit margin percentage primarily resulted from adding a higher percent of activations in the California market in our Mobile Services segment, and sourcing lower per subscriber network costs. Total operating expenses were $3.3 million, down (18.8%) compared to $4.1 million. This decrease was primarily due to lower payroll and related expenses associated with the reduction of headcount in our IM Telecom subsidiary and lower application development costs in our Apeiron Systems subsidiary. GAAP net loss was $(2,105,169) or $(0.05) per diluted share (based on 43.5 million weighted average shares), compared to net income of $7 million, or $0.16 per diluted share (based on 43.3 million weighted average shares). This decrease was a result of the gain on sale recognized as part of our sale of 49% interest in IM Telecom in the first quarter of 2024. Non-GAAP net loss was $(1,619,014) million, or $(0.04) per diluted share, compared to non-GAAP net income of $7.5 million, or $0.17 per diluted share. About KonaTel KonaTel provides a variety of retail and wholesale telecommunications services, including mobile voice/text/data service supported by national U.S. mobile networks, mobile numbers, SMS/MMS services, IoT mobile data service, and a range of hosted cloud services. KonaTel's subsidiary, Apeiron Systems ( is a global cloud communications service provider employing a dynamic "as a service" (CPaaS/UCaaS/CCaaS/PaaS) platform. Apeiron provides voice, messaging, SD-WAN, and platform services using its national cloud network. All Apeiron's services can be accessed through legacy interfaces and rich communications APIs. KonaTel's other subsidiary, Infiniti Mobile ( is an FCC authorized national wireless ACP and Lifeline carrier with an FCC approved wireless Lifeline Compliance Plan, licensed to provide government subsidized cellular service to low-income American families across forty (40) states. KonaTel is headquartered in Plano, Texas. Safe Harbor Statement This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Press Release. This Press Release should be considered in light of the disclosures contained in the filings of KonaTel and its "forward-looking statements" in such filings that are contained in the EDGAR Archives of the SEC at Contacts D. Sean McEweninquiries@ -- Unaudited Balance Sheets and Statements of Operations Follow - KonaTel, Balance Sheets(unaudited) June 30, 2025 December 31, 2024 Assets Current Assets Cash and Cash Equivalents $ 1,491,346 $ 1,679,345 Accounts Receivable, Net 509,571 1,533,015 Inventory, Net 118,242 163,063 Prepaid Expenses 75,349 94,496 Other Current Assets 310,988 112,170 Total Current Assets 2,505,496 3,582,089 Property and Equipment, Net 13,563 15,128 Other Assets Intangible Assets, Net 323,468 323,468 Right of Use Asset 257,499 319,549 Notes Receivable 850,000 1,000,000 Other Assets 74,328 74,328 Total Other Assets 1,505,295 1,717,345 Total Assets $ 4,024,354 $ 5,314,562 Liabilities and Stockholders' Equity Current Liabilities Accounts Payable and Accrued Expenses $ 2,675,605 $ 2,277,597 Right of Use Operating Lease Obligation - Current 78,457 113,740 Income Tax Payable 184,051 184,051 Total Current Liabilities 2,938,113 2,575,388 Long Term Liabilities Right of Use Operating Lease Obligation - Long Term 195,999 227,776 Total Long-Term Liabilities 195,999 227,776 Total Liabilities 3,134,112 2,803,164 Commitments and Contingencies Stockholders' Equity Common stock, $.001 par value, 50,000,000 shares authorized 43,541,140 outstanding and issued at June 30, 2025, and 43,503,658 outstanding and issued at December 31, 2024 43,541 43,504 Additional Paid In Capital 10,699,743 10,215,767 Accumulated Deficit (9,853,042 ) (7,747,873 ) Total Stockholders' Equity 890,242 2,511,398 Total Liabilities and Stockholders' Equity $ 4,024,354 $ 5,314,562 KonaTel, Statements of Operations(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 2,158,656 $ 4,343,179 $ 4,327,370 $ 9,979,016 Cost of Revenue 1,608,416 3,443,472 3,125,237 7,951,804 Gross Profit 550,240 899,707 1,202,133 2,027,212 Operating Expenses Payroll and Related Expenses 1,081,633 1,341,046 2,192,333 2,793,146 Operating and Maintenance 2,069 1,421 3,489 2,965 Credit Loss 13,910 - 13,910 1,448 Professional and Other Expenses 325,750 231,302 483,181 341,525 Utilities and Facilities 48,528 59,332 94,939 110,118 Depreciation and Amortization 782 2,449 1,565 4,899 General and Administrative 64,975 44,573 114,962 105,968 Marketing and Advertising 5,396 27,031 10,482 61,027 Application Development Costs 172,967 387,800 351,493 593,883 Taxes and Insurance 32,788 59,115 63,981 113,550 Total Operating Expenses 1,748,798 2,154,069 3,330,335 4,128,529 Operating Loss (1,198,558 ) (1,254,362 ) (2,128,202 ) (2,101,317 ) Other Income and Expense Gain on Sale - - - 9,247,726 Interest Expense - - (577 ) (104,329 ) Other Income/(Expense), net 10,917 (4,763 ) 23,610 (68,693 ) Total Other Income and Expenses 10,917 (4,763 ) 23,033 9,074,704 Income (Loss) Before Income Taxes (1,187,641 ) (1,259,125 ) (2,105,169 ) 6,973,387 Income Tax Expense (Benefit) - (149,428 ) - - Net Income (Loss) $ (1,187,641 ) $ (1,109,697 ) $ (2,105,169 ) $ 6,973,387 Earnings (Loss) per Share Basic $ (0.03 ) $ (0.03 ) $ (0.05 ) $ 0.16 Diluted $ (0.03 ) $ (0.03 ) $ (0.05 ) $ 0.16 Weighted Average Outstanding Shares Basic 43,537,102 43,412,602 43,536,341 43,301,670 Diluted 43,537,102 43,412,602 43,536,341 43,301,670 SOURCE: KonaTel, Inc. View the original press release on ACCESS Newswire
Miami Herald
an hour ago
- Miami Herald
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held on August 19, 2025 (the "Annual Meeting"). Seven proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting and supplemental information filed with the Securities and Exchange Commission on July 21, 2025 and as amended on August 6, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at The proxy statement is also available on the Company's corporate website. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference, and statements regarding Jaguar's planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
